Xsphera Biosciences Inc’s Post

Advancing extracellular vesicle-enabled liquid biopsy for lung cancer detection: in this concise review article, Adeel Khan, Nongyue He at Southeast University and Faisal Raza 费赛 at Shanghai Jiao Tong University explored the potential of EV-based liquid biopsies for lung cancer, highlighting the strengths, weaknesses, and challenges of current EV isolation and analysis techniques for broader clinical application https://lnkd.in/eEhRHctd They noted that EV-based liquid biopsies offer promising opportunities for developing innovative diagnostic and prognostic tools for lung cancer. #extracellularvesicles #exosomes #lungcancer #liquibiopsy #Vesiculab

Want to get up to scratch on the latest 3D Cancer Models? Download our whitepaper! 👉 Swipe through to see what you'll learn, including six applications of our 3D tumor modeling capabilities. Explore these applications and other exciting topics in the whitepaper and discover how MIMETAS can help you close the translational gap in cancer drug discovery: https://lnkd.in/eS9r_6-h #CancerResearch #DrugDiscovery #Oncology #OncologyResearch #CancerDrugDiscovery

👏🏿 Sara Sdelci, Group Leader at the #CRG, has received the VI FERO-MANGO Award in Breast Cancer from the Fundación Fero She has been selected for her project on PARP1 inhibitors (PARP1i). "We will particularly focus on triple-negative breast cancer, a type of cancer for which PARP1 inhibitors are currently the only targeted therapy available. To develop our first asset, we will perform high-throughput imaging studies on patient-derived xenografts (PDX) and on patient biopsies...This tool will significantly improve the selection of patients for PARP1i treatments, increasing the chances of therapeutic success,” explains Dr. Sdelci. 👉🏿 https://lnkd.in/dPJ2PVRj 📷 Sara Sdelci with Isak Andic, President of MANGO #BecasFERO #FEROCuentaContigo #Investigación #Feritos

Reliably determining HER2 status from a blood test represents a significant opportunity to advance the standard of care for patients with breast cancer given the availability of effective HER2 directed therapies. This is just one mission we are making rapid progress on at Precede Biosciences in partnership with leading investigators in the field at the Dana-Farber Cancer Institute To learn more 👇🏾👇🏾 #healthcare #precisionmedicine #oncology #drugdevelopment

For Triple-Negative Breast Cancer (TNBC), LAR subtype breast cancer: VincoAI, successfully generated a 10mer peptide, VLAR-46-10MEROX, that targets the active site of Luminal androgen receptor (LAR) by computational peptide-protein docking simulations. Although these in-silico results support VincoAI peptide potential as LAR blocker, in vitro and in vivo validation is still needed. #tnbc #generativeai #vincoai #vincogen

A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer. An article was recently published in an important journal, highlighting the potential breakthroughs of THIO in lung cancer. Read here: https://lnkd.in/dJC-v8pH #Oncology #OncNews #Science

Journal of cancer Therapy and Research Bone cancer is a rare condition that can develop in the bones. Rare bone tumors include bone cancer and cartilage cancer, which can have different names depending on where they are in the body. For example, a chordoma tumor that forms at the skull base might be called a clival tumor, and one that forms near the tailbone might be called a sacral tumor. For more information visit our journal: https://lnkd.in/dJe3Huxs Submit your recent work at: cancer@genesispub.org For anymore queries whatsApp at: +1 (438) 699-5365 #bonecancer #cancerresearch #oncology #postdoc #researchers #curepatient #openaccess #submissionopen

Signatera is a blood test that can identify molecular residual disease, or recurrent cancer, sooner than existing methods, by detecting the presence of ctDNA. Signatera is a personalized, tumor-informed test optimized to detect ctDNA with high sensitivity and specificity. https://lnkd.in/eSKGUrBq #Cancer #Oncology #CirculatingTumorDNA #ctDNA #Signatera

🌟 𝗡𝗲𝘄 𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝗔𝗹𝗲𝗿𝘁: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗰𝗮𝗻𝗰𝗲𝗿” 🌟   Watch this new episode of 'What’s New Doc' in prostate cancer in which Prof Bertrand Tombal and Prof Steven Joniau discuss the updated results of ProtecT, solidifying active surveillance as the preferred treatment of localized, (intermediate)-low risk prostate cancer.   👇 Watch all WND PCa videos - link in the comments! #MediMix #ProstateCancer #Oncology

The role of cancer-associated fibroblasts (CAFs) in non-small cell lung cancer (NSCLC) tumor microenvironment. Key Points: CAFs contribute to drug resistance, cancer stem cell regulation, and immune suppression. Targeting CAFs may improve NSCLC treatment outcomes. Heterogeneity among CAFs necessitates the identification of specific markers for effective therapies. Various signaling pathways (e.g., TGF-β, IL-6) are involved in CAF-mediated tumor progression and resistance. This article concludes that "CAF-targeted therapies hold potential for enhancing NSCLC treatment efficacy." #cancer #cancerresearch #CAF cells #Tumor microenvironment #NSCLC